REGENXBIO Inc. (RGNX)

NMS – Real vaqt narxi. Valyuta: USD

10.24

+0.16 (1.59%)

Yopilishda: May 12, 2026, 4:00 PM EDT

07.05.2026

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

ROCKVILLE, Md., May 7, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 2026 American Society of Gene & Cell Therapy Annual Meeting ("ASGCT 2026") taking place May 11-15, 2026, in Boston, Massachusetts.

06.05.2026

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

-- Company will also report first quarter 2026 financial results and operational highlights -- ROCKVILLE, Md., May 6, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast on Thursday, May 14, 2026, at 8:00 a.m.

15.04.2026

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

LOS ANGELES, April 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

14.04.2026

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

NEW YORK, April 14, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the "Class Period"), of the important April 14, 2026 lead plaintiff deadline. So what: If you purchased REGENXBIO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

14.04.2026

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against REGENXBIO Inc. (NASDAQ: RGNX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired REGENXBIO securities between February 9, 2022 and January 27, 2026, both dates inclusive (the "Class Period").

14.04.2026

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). REGENXBIO is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that REGENXBIO, Inc.

14.04.2026

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

NEW YORK--(BUSINESS WIRE)---- $RGNX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) and reminds investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

15.04.2026

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

14.04.2026

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

14.04.2026

REGENXBIO Inc. (RGNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

REGENXBIO Inc. (RGNX)

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Videolar

No Data

Press-relizlar

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Videolar

No Data

Press-relizlar

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Search stocks

REGENXBIO Inc. (RGNX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

REGENXBIO Inc. (RGNX)

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Videolar

No Data

Press-relizlar

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Videolar

No Data

Press-relizlar

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm